Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Donna Carey who wrote (1220)	12/8/1998 11:16:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 56535

Anybody up for a little microcap biotech? Heh heh, probably not, I'm not even sure if I will try to trade this one, since I already own a chunk for holding, and it is usually not tradable. Anyway, the company is Biotransplant, BTRN here is the news item biz.yahoo.com (snip)Further analysis indicated that six of 11 evaluable patients achieved a complete remission and two of 11 a partial remission, despite having advanced cancers that did not respond to other treatments. Seven of the 15 patients who received the new therapy are alive and progression free at a median period of 169 days (range, 27 to 475 days) following BMT. Dr. Sykes and colleagues separately reported an evaluation of five patients that received the new BMT therapy after experiencing a relapse in their blood cell cancers. In four of these five patients, chimeric immune systems were established without the development of severe GvHD. These patients showed potent anti-tumor activity against the cancerous blood cells, with four complete remissions and one partial remission in this subgroup, and retained the ability to mount immune responses against other foreign elements. (snip) Be careful with this one, I watched it a long time and have 1000 shares which I bought when it was below book value! It is still obviously a bargain, hell, probably a bargain at $5, but every time I think I see a sure thing, it backfires. A lot of these microcap biotechs have retreated to one or two times book over the last few years. I suppose it is very reasonable for things with high burn rates to trade near book if they have no prospects, but as far as I can tell, BTRN has real prospects. I over-rely on the biotech freaks here on SI, but I've been studying lately, Graft v Host disease is obviously a very important area to be doing cutting edge science...BTRN is right there in the thick of things. Obviously one to watch, a very good choice to own long term, and maybe even tradable today for a change. --MM